Diabetes

Template:Redirect
Template:Pp-semi-indef
Template:Infobox medical condition (new)
**Diabetes mellitus** (**DM**), commonly referred to as **diabetes**, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst, and increased hunger. If left untreated, diabetes can cause many complications. Acute complications can include diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Serious long-term complications include cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and damage to the eyes.

Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body not responding properly to the insulin produced. There are three main types of diabetes mellitus:

* Type 1 DM results from the pancreas' failure to produce enough insulin due to loss of beta cells. This form was previously referred to as "insulin-dependent diabetes mellitus" (IDDM) or "juvenile diabetes". The cause is unknown.
* Type 2 DM begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses, a lack of insulin may also develop. This form was previously referred to as "non insulin-dependent diabetes mellitus" (NIDDM) or "adult-onset diabetes". The most common cause is excessive body weight and insufficient exercise.
* Gestational diabetes is the third main form, and occurs when pregnant women without a previous history of diabetes develop high blood sugar levels.

Prevention and treatment involve maintaining a healthy diet, regular physical exercise, a normal body weight, and avoiding use of tobacco. Control of blood pressure and maintaining proper foot care are important for people with the disease. Type 1 DM must be managed with insulin injections. Type 2 DM may be treated with medications with or without insulin. Insulin and some oral medications can cause low blood sugar. Weight loss surgery in those with obesity is sometimes an effective measure in those with type 2 DM. Gestational diabetes usually resolves after the birth of the baby.

Template:Asof, an estimated 415 million people had diabetes worldwide, with type 2 DM making up about 90% of the cases. This represents 8.3% of the adult population, with equal rates in both women and men. Template:Asof, trends suggested the rate would continue to rise. Diabetes at least doubles a person's risk of early death. From 2012 to 2015, approximately 1.5 to 5.0 million deaths each year resulted from diabetes. The global economic cost of diabetes in 2014 was estimated to be Template:USD billion. In the United States, diabetes cost $245 billion in 2012.

## Signs and symptoms

 File:Main symptoms of diabetes.svg
The classic symptoms of untreated diabetes are unintended weight loss, polyuria (increased urination), polydipsia (increased thirst), and polyphagia (increased hunger). Symptoms may develop rapidly (weeks or months) in type 1 DM, while they usually develop much more slowly and may be subtle or absent in type 2 DM.

Several other signs and symptoms can mark the onset of diabetes although they are not specific to the disease. In addition to the known ones above, they include blurred vision, headache, fatigue, slow healing of cuts, and itchy skin. Prolonged high blood glucose can cause glucose absorption in the lens of the eye, which leads to changes in its shape, resulting in vision changes. A number of skin rashes that can occur in diabetes are collectively known as diabetic dermadromes.

### Diabetic emergencies

Low blood sugar (hypoglycemia), is common in people with type 1 and type 2 DM. Most cases are mild and are not considered medical emergencies. Effects can range from feelings of unease, sweating, trembling, and increased appetite in mild cases to more serious effects such as confusion, changes in behavior such as aggressiveness, seizures, unconsciousness, and (rarely) permanent brain damage or death in severe cases. Moderately low blood sugar may easily be mistaken for drunkenness; rapid breathing and sweating, cold, pale skin are characteristic of low blood sugar but not definitive. Mild to moderate cases are self-treated by eating or drinking something high in sugar. Severe cases can lead to unconsciousness and must be treated with intravenous glucose or injections with glucagon.

People (usually with type 1 DM) may also experience episodes of diabetic ketoacidosis (DKA), a metabolic disturbance characterized by nausea, vomiting and abdominal pain, the smell of acetone on the breath, deep breathing known as Kussmaul breathing, and in severe cases a decreased level of consciousness.

A rare but equally severe possibility is hyperosmolar hyperglycemic state (HHS), which is more common in type 2 DM and is mainly the result of dehydration.

### Complications

Template:Main

 File:Diabetes complications.jpg
All forms of diabetes increase the risk of long-term complications. These typically develop after many years (10–20) but may be the first symptom in those who have otherwise not received a diagnosis before that time.

The major long-term complications relate to damage to blood vessels. Diabetes doubles the risk of cardiovascular disease and about 75% of deaths in diabetics are due to coronary artery disease. Other macrovascular diseases include stroke, and peripheral artery disease.

The primary complications of diabetes due to damage in small blood vessels include damage to the eyes, kidneys, and nerves. Damage to the eyes, known as diabetic retinopathy, is caused by damage to the blood vessels in the retina of the eye, and can result in gradual vision loss and eventual blindness. Diabetes also increases the risk of having glaucoma, cataracts, and other eye problems. It is recommended that diabetics visit an eye doctor once a year. Damage to the kidneys, known as diabetic nephropathy, can lead to tissue scarring, urine protein loss, and eventually chronic kidney disease, sometimes requiring dialysis or kidney transplantation. Damage to the nerves of the body, known as diabetic neuropathy, is the most common complication of diabetes. The symptoms can include numbness, tingling, pain, and altered pain sensation, which can lead to damage to the skin. Diabetes-related foot problems (such as diabetic foot ulcers) may occur, and can be difficult to treat, occasionally requiring amputation. Additionally, proximal diabetic neuropathy causes painful muscle atrophy and weakness.

There is a link between cognitive deficit and diabetes. Compared to those without diabetes, those with the disease have a 1.2 to 1.5-fold greater rate of decline in cognitive function. Being diabetic, especially when on insulin, increases the risk of falls in older people.

## Causes

Comparison of type 1 and 2 diabetes
 Age at onset
 Body size
 Endogenous insulin
 Prevalence

Diabetes mellitus is classified into four broad categories: type 1, type 2, gestational diabetes, and "other specific types". The "other specific types" are a collection of a few dozen individual causes. Diabetes is a more variable disease than once thought and people may have combinations of forms. The term "diabetes", without qualification, usually refers to diabetes mellitus.

### Type 1

Template:Main
Type 1 diabetes mellitus is characterized by loss of the insulin-producing beta cells of the pancreatic islets, leading to insulin deficiency. This type can be further classified as immune-mediated or idiopathic. The majority of type 1 diabetes is of the immune-mediated nature, in which a T cell-mediated autoimmune attack leads to the loss of beta cells and thus insulin. It causes approximately 10% of diabetes mellitus cases in North America and Europe. Most affected people are otherwise healthy and of a healthy weight when onset occurs. Sensitivity and responsiveness to insulin are usually normal, especially in the early stages. Type 1 diabetes can affect children or adults, but was traditionally termed "juvenile diabetes" because a majority of these diabetes cases were found in children.Template:Citation needed

"Brittle" diabetes, also known as unstable diabetes or labile diabetes, is a term that was traditionally used to describe the dramatic and recurrent swings in glucose levels, often occurring for no apparent reason in insulin-dependent diabetes. This term, however, has no biologic basis and should not be used. Still, type 1 diabetes can be accompanied by irregular and unpredictable high blood sugar levels, frequently with ketosis, and sometimes with serious low blood sugar levels. Other complications include an impaired counterregulatory response to low blood sugar, infection, gastroparesis (which leads to erratic absorption of dietary carbohydrates), and endocrinopathies (e.g., Addison's disease). These phenomena are believed to occur no more frequently than in 1% to 2% of persons with type 1 diabetes.

 File:Type 1 Diabetes Mellitus.jpg
Type 1 diabetes is partly inherited, with multiple genes, including certain HLA genotypes, known to influence the risk of diabetes. In genetically susceptible people, the onset of diabetes can be triggered by one or more environmental factors, such as a viral infection or diet. Several viruses have been implicated, but to date there is no stringent evidence to support this hypothesis in humans. Among dietary factors, data suggest that gliadin (a protein present in gluten) may play a role in the development of type 1 diabetes, but the mechanism is not fully understood.

### Type 2

Template:Main

 File:Type 2 Diabetes Mellitus.jpg
Type 2 DM is characterized by insulin resistance, which may be combined with relatively reduced insulin secretion. The defective responsiveness of body tissues to insulin is believed to involve the insulin receptor. However, the specific defects are not known. Diabetes mellitus cases due to a known defect are classified separately. Type 2 DM is the most common type of diabetes mellitus.

In the early stage of type 2, the predominant abnormality is reduced insulin sensitivity. At this stage, high blood sugar can be reversed by a variety of measures and medications that improve insulin sensitivity or reduce the liver's glucose production.

Type 2 DM is primarily due to lifestyle factors and genetics. A number of lifestyle factors are known to be important to the development of type 2 DM, including obesity (defined by a body mass index of greater than 30), lack of physical activity, poor diet, stress, and urbanization. Excess body fat is associated with 30% of cases in those of Chinese and Japanese descent, 60–80% of cases in those of European and African descent, and 100% of Pima Indians and Pacific Islanders. Even those who are not obese often have a high waist–hip ratio.

Dietary factors also influence the risk of developing type 2 DM. Consumption of sugar-sweetened drinks in excess is associated with an increased risk. The type of fats in the diet is also important, with saturated fat and trans fats increasing the risk and polyunsaturated and monounsaturated fat decreasing the risk. Eating lots of white rice, and other starches, also may increase the risk of diabetes. A lack of physical activity is believed to cause 7% of cases.

### Gestational diabetes

Template:Main
Gestational diabetes mellitus (GDM) resembles type 2 DM in several respects, involving a combination of relatively inadequate insulin secretion and responsiveness. It occurs in about 2–10% of all pregnancies and may improve or disappear after delivery. However, after pregnancy approximately 5–10% of women with GDM are found to have DM, most commonly type 2. GDM is fully treatable, but requires careful medical supervision throughout the pregnancy. Management may include dietary changes, blood glucose monitoring, and in some cases, insulin may be required.

Though it may be transient, untreated GDM can damage the health of the fetus or mother. Risks to the baby include macrosomia (high birth weight), congenital heart and central nervous system abnormalities, and skeletal muscle malformations. Increased levels of insulin in a fetus's blood may inhibit fetal surfactant production and cause infant respiratory distress syndrome. A high blood bilirubin level may result from red blood cell destruction. In severe cases, perinatal death may occur, most commonly as a result of poor placental perfusion due to vascular impairment. Labor induction may be indicated with decreased placental function. A caesarean section may be performed if there is marked fetal distress or an increased risk of injury associated with macrosomia, such as shoulder dystocia.

### Maturity onset diabetes of the young

Maturity onset diabetes of the young (MODY) is a rare autosomal dominant inherited form of diabetes, due to one of several single-gene mutations causing defects in insulin production. It is significantly less common than the three main types. The name of this disease refers to early hypotheses as to its nature. Being due to a defective gene, this disease varies in age at presentation and in severity according to the specific gene defect; thus there are at least 13 subtypes of MODY. People with MODY often can control it without using insulin.

### Other types

Prediabetes indicates a condition that occurs when a person's blood glucose levels are higher than normal but not high enough for a diagnosis of type 2 DM.
Many people who later develop type 2 DM spend many years in a state of prediabetes.

Latent autoimmune diabetes of adults (LADA) is a condition in which type 1 DM develops in adults. Adults with LADA are frequently initially misdiagnosed as having type 2 DM, based on age rather than cause.

Some cases of diabetes are caused by the body's tissue receptors not responding to insulin (even when insulin levels are normal, which is what separates it from type 2 diabetes); this form is very uncommon. Genetic mutations (autosomal or mitochondrial) can lead to defects in beta cell function. Abnormal insulin action may also have been genetically determined in some cases. Any disease that causes extensive damage to the pancreas may lead to diabetes (for example, chronic pancreatitis and cystic fibrosis). Diseases associated with excessive secretion of insulin-antagonistic hormones can cause diabetes (which is typically resolved once the hormone excess is removed). Many drugs impair insulin secretion and some toxins damage pancreatic beta cells. The ICD-10 (1992) diagnostic entity, *malnutrition-related diabetes mellitus* (MRDM or MMDM, ICD-10 code E12), was deprecated by the World Health Organization (WHO) when the current taxonomy was introduced in 1999.

Other forms of diabetes mellitus include congenital diabetes, which is due to genetic defects of insulin secretion, cystic fibrosis-related diabetes, steroid diabetes induced by high doses of glucocorticoids, and several forms of monogenic diabetes.

"Type 3 diabetes" has been suggested as a term for Alzheimer's disease as the underlying processes may involve insulin resistance by the brain.

The following is a comprehensive list of other causes of diabetes:
Template:Col-begin
Template:Col-2

* Genetic defects of β-cell function
	+ Maturity onset diabetes of the young
	+ Mitochondrial DNA mutations
* Genetic defects in insulin processing or insulin action
	+ Defects in proinsulin conversion
	+ Insulin gene mutations
	+ Insulin receptor mutations
* Exocrine pancreatic defects
	+ Chronic pancreatitis
	+ Pancreatectomy
	+ Pancreatic neoplasia
	+ Cystic fibrosis
	+ Hemochromatosis
	+ Fibrocalculous pancreatopathy

Template:Col-2

* Endocrinopathies
	+ Growth hormone excess (acromegaly)
	+ Cushing syndrome
	+ Hyperthyroidism
	+ Pheochromocytoma
	+ Glucagonoma
* Infections
	+ Cytomegalovirus infection
	+ Coxsackievirus B
* Drugs
	+ Glucocorticoids
	+ Thyroid hormone
	+ β-adrenergic agonists
	+ Statins

Template:Col-end

A 2018 study suggested that three types should be abandoned as too simplistic. It classified diabetes into five subgroups, with what is typically described as type 1 and autoimmune late-onset diabetes categorized as one group, whereas type 2 encompasses four categories. This is hoped to improve diabetes treatment by tailoring it more specifically to the subgroups.

## Pathophysiology

 File:Suckale08 fig3 glucose insulin day.png
 File:Glucose-insulin-release.svg
Insulin is the principal hormone that regulates the uptake of glucose from the blood into most cells of the body, especially liver, adipose tissue and muscle, except smooth muscle, in which insulin acts via the IGF-1. Therefore, deficiency of insulin or the insensitivity of its receptors play a central role in all forms of diabetes mellitus.

The body obtains glucose from three main sources: the intestinal absorption of food; the breakdown of glycogen (glycogenolysis), the storage form of glucose found in the liver; and gluconeogenesis, the generation of glucose from non-carbohydrate substrates in the body. Insulin plays a critical role in balancing glucose levels in the body. Insulin can inhibit the breakdown of glycogen or the process of gluconeogenesis, it can stimulate the transport of glucose into fat and muscle cells, and it can stimulate the storage of glucose in the form of glycogen.

Insulin is released into the blood by beta cells (β-cells), found in the islets of Langerhans in the pancreas, in response to rising levels of blood glucose, typically after eating. Insulin is used by about two-thirds of the body's cells to absorb glucose from the blood for use as fuel, for conversion to other needed molecules, or for storage. Lower glucose levels result in decreased insulin release from the beta cells and in the breakdown of glycogen to glucose. This process is mainly controlled by the hormone glucagon, which acts in the opposite manner to insulin.

If the amount of insulin available is insufficient, or if cells respond poorly to the effects of insulin (insulin insensitivity or insulin resistance), or if the insulin itself is defective, then glucose will not be absorbed properly by the body cells that require it, and it will not be stored appropriately in the liver and muscles. The net effect is persistently high levels of blood glucose, poor protein synthesis, and other metabolic derangements, such as acidosis.

When the glucose concentration in the blood remains high over time, the kidneys will reach a threshold of reabsorption, and glucose will be excreted in the urine (glycosuria). This increases the osmotic pressure of the urine and inhibits reabsorption of water by the kidney, resulting in increased urine production (polyuria) and increased fluid loss. Lost blood volume will be replaced osmotically from water held in body cells and other body compartments, causing dehydration and increased thirst (polydipsia).

## Diagnosis

Template:See also
Template:OGTT
Diabetes mellitus is characterized by recurrent or persistent high blood sugar, and is diagnosed by demonstrating any one of the following:

* Fasting plasma glucose level ≥ 7.0 mmol/l (126 mg/dl)
* Plasma glucose ≥ 11.1 mmol/l (200 mg/dl) two hours after a 75 gram oral glucose load as in a glucose tolerance test (OGTT)
* Symptoms of high blood sugar and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dl)
* Glycated hemoglobin (HbA1C) ≥ 48 mmol/mol (≥ 6.5 DCCT %).

A positive result, in the absence of unequivocal high blood sugar, should be confirmed by a repeat of any of the above methods on a different day. It is preferable to measure a fasting glucose level because of the ease of measurement and the considerable time commitment of formal glucose tolerance testing, which takes two hours to complete and offers no prognostic advantage over the fasting test. According to the current definition, two fasting glucose measurements above 7.0 mmol/l (126 mg/dl) is considered diagnostic for diabetes mellitus.

Per the WHO, people with fasting glucose levels from 6.1 to 6.9 mmol/l (110 to 125 mg/dl) are considered to have impaired fasting glucose. people with plasma glucose at or above 7.8 mmol/l (140 mg/dl), but not over 11.1 mmol/l (200 mg/dl), two hours after a 75 gram oral glucose load are considered to have impaired glucose tolerance. Of these two prediabetic states, the latter in particular is a major risk factor for progression to full-blown diabetes mellitus, as well as cardiovascular disease. The American Diabetes Association (ADA) since 2003 uses a slightly different range for impaired fasting glucose of 5.6 to 6.9 mmol/l (100 to 125 mg/dl).

Glycated hemoglobin is better than fasting glucose for determining risks of cardiovascular disease and death from any cause.

## Prevention

Template:See also
There is no known preventive measure for type 1 diabetes. Type 2 diabetesTemplate:Sndwhich accounts for 85–90% of all casesTemplate:Sndcan often be prevented or delayed by maintaining a normal body weight, engaging in physical activity, and consuming a healthy diet. Higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%. Dietary changes known to be effective in helping to prevent diabetes include maintaining a diet rich in whole grains and fiber, and choosing good fats, such as the polyunsaturated fats found in nuts, vegetable oils, and fish. Limiting sugary beverages and eating less red meat and other sources of saturated fat can also help prevent diabetes. Tobacco smoking is also associated with an increased risk of diabetes and its complications, so smoking cessation can be an important preventive measure as well.

The relationship between type 2 diabetes and the main modifiable risk factors (excess weight, unhealthy diet, physical inactivity and tobacco use) is similar in all regions of the world. There is growing evidence that the underlying determinants of diabetes are a reflection of the major forces driving social, economic and cultural change: globalization, urbanization, population aging, and the general health policy environment.

## Management

Template:Main

 File:ABCs of Diabetes.webm
Diabetes mellitus is a chronic disease, for which there is no known cure except in very specific situations. Management concentrates on keeping blood sugar levels as close to normal, without causing low blood sugar. This can usually be accomplished with a healthy diet, exercise, weight loss, and use of appropriate medications (insulin in the case of type 1 diabetes; oral medications, as well as possibly insulin, in type 2 diabetes).Template:Mcn

Learning about the disease and actively participating in the treatment is important, since complications are far less common and less severe in people who have well-managed blood sugar levels. The goal of treatment is an HbA1C level of 6.5%, but should not be lower than that, and may be set higher. Attention is also paid to other health problems that may accelerate the negative effects of diabetes. These include smoking, elevated cholesterol levels, obesity, high blood pressure, and lack of regular exercise. Specialized footwear is widely used to reduce the risk of ulceration, or re-ulceration, in at-risk diabetic feet. Evidence for the efficacy of this remains equivocal, however.

### Lifestyle

Template:See also
People with diabetes can benefit from education about the disease and treatment, good nutrition to achieve a normal body weight, and exercise, with the goal of keeping both short-term and long-term blood glucose levels within acceptable bounds. In addition, given the associated higher risks of cardiovascular disease, lifestyle modifications are recommended to control blood pressure.

There is no single dietary pattern that is best for all people with diabetes. For overweight people with type 2 diabetes, any diet that the person will adhere to and achieve weight loss on is effective.

### Medications

#### Glucose control

Template:See also
Medications used to treat diabetes do so by lowering blood sugar levels. There is broad consensus that when people with diabetes maintain tight glucose control (also called "tight glycemic control") -- keeping the glucose levels in their blood within normal ranges - that they fewer complications like kidney problems and [diabetic retinopathy|eye problems]]. There is however debate as to whether this is cost effective for people later in life.

There are a number of different classes of anti-diabetic medications. Some are available by mouth, such as metformin, while others are only available by injection such as GLP-1 agonists. Type 1 diabetes can only be treated with insulin, typically with a combination of regular and NPH insulin, or synthetic insulin analogs.Template:Citation needed

Metformin is generally recommended as a first line treatment for type 2 diabetes, as there is good evidence that it decreases mortality. It works by decreasing the liver's production of glucose. Several other groups of drugs, mostly given by mouth, may also decrease blood sugar in type II DM. These include agents that increase insulin release, agents that decrease absorption of sugar from the intestines, and agents that make the body more sensitive to insulin. When insulin is used in type 2 diabetes, a long-acting formulation is usually added initially, while continuing oral medications. Doses of insulin are then increased to effect.

#### Blood pressure

Since cardiovascular disease is a serious complication associated with diabetes, some have recommended blood pressure levels below 130/80 mmHg. However, evidence supports less than or equal to somewhere between 140/90 mmHg to 160/100 mmHg; the only additional benefit found for blood pressure targets beneath this range was an isolated decrease in stroke risk, and this was accompanied by an increased risk of other serious adverse events. A 2016 review found potential harm to treating lower than 140 mmHg. Among medications that lower blood pressure, angiotensin converting enzyme inhibitors (ACEIs) improve outcomes in those with DM while the similar medications angiotensin receptor blockers (ARBs) do not. Aspirin is also recommended for people with cardiovascular problems, however routine use of aspirin has not been found to improve outcomes in uncomplicated diabetes.

### Surgery

Weight loss surgery in those with obesity and type two diabetes is often an effective measure. Many are able to maintain normal blood sugar levels with little or no medications following surgery and long-term mortality is decreased. There is, however, a short-term mortality risk of less than 1% from the surgery. The body mass index cutoffs for when surgery is appropriate are not yet clear. It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control.

A pancreas transplant is occasionally considered for people with type 1 diabetes who have severe complications of their disease, including end stage kidney disease requiring kidney transplantation.

### Support

In countries using a general practitioner system, such as the United Kingdom, care may take place mainly outside hospitals, with hospital-based specialist care used only in case of complications, difficult blood sugar control, or research projects. In other circumstances, general practitioners and specialists share care in a team approach. Home telehealth support can be an effective management technique.

## Epidemiology

Template:Main

 File:Diabetes world map - 2000.svg
 File:Diabetes mellitus world map-Deaths per million persons-WHO2012.svg
As of 2016, 422 million people have diabetes worldwide, up from an estimated 382 million people in 2013 and from 108 million in 1980. Accounting for the shifting age structure of the global population, the prevalence of diabetes is 8.5% among adults, nearly double the rate of 4.7% in 1980. Type 2 makes up about 90% of the cases. Some data indicate rates are roughly equal in women and men, but male excess in diabetes has been found in many populations with higher type 2 incidence, possibly due to sex-related differences in insulin sensitivity, consequences of obesity and regional body fat deposition, and other contributing factors such as high blood pressure, tobacco smoking, and alcohol intake.

The WHO estimates that diabetes mellitus resulted in 1.5 million deaths in 2012, making it the 8th leading cause of death. However another 2.2 million deaths worldwide were attributable to high blood glucose and the increased risks of cardiovascular disease and other associated complications (e.g. kidney failure), which often lead to premature death and are often listed as the underlying cause on death certificates rather than diabetes. For example, in 2014, the International Diabetes Federation (IDF) estimated that diabetes resulted in 4.9 million deaths worldwide, using modeling to estimate the total number of deaths that could be directly or indirectly attributed to diabetes.

Diabetes mellitus occurs throughout the world but is more common (especially type 2) in more developed countries. The greatest increase in rates has however been seen in low- and middle-income countries, where more than 80% of diabetic deaths occur. The fastest prevalence increase is expected to occur in Asia and Africa, where most people with diabetes will probably live in 2030. The increase in rates in developing countries follows the trend of urbanization and lifestyle changes, including increasingly sedentary lifestyles, less physically demanding work and the global nutrition transition, marked by increased intake of foods that are high energy-dense but nutrient-poor (often high in sugar and saturated fats, sometimes referred to as the "Western-style" diet). The global prevalence of diabetes might increase by 55% between 2013 and 2035.

## History

Template:Main
Diabetes was one of the first diseases described, with an Egyptian manuscript from Template:Abbr 1500 BCE mentioning "too great emptying of the urine". The Ebers papyrus includes a recommendation for a drink to be taken in such cases. The first described cases are believed to be of type 1 diabetes. Indian physicians around the same time identified the disease and classified it as *madhumeha* or "honey urine", noting the urine would attract ants.

The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Apollonius of Memphis. The disease was considered rare during the time of the Roman empire, with Galen commenting he had only seen two cases during his career. This is possibly due to the diet and lifestyle of the ancients, or because the clinical symptoms were observed during the advanced stage of the disease. Galen named the disease "diarrhea of the urine" (diarrhea urinosa).

The earliest surviving work with a detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rdTemplate:Nbspcentury CE). He described the symptoms and the course of the disease, which he attributed to the moisture and coldness, reflecting the beliefs of the "Pneumatic School". He hypothesized a correlation of diabetes with other diseases, and he discussed differential diagnosis from the snakebite which also provokes excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.

Type 1 and type 2 diabetes were identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400–500 CE with type 1 associated with youth and type 2 with being overweight. The term "mellitus" or "from honey" was added by the Briton John Rolle in the late 1700s to separate the condition from diabetes insipidus, which is also associated with frequent urination. Effective treatment was not developed until the early part of the 20th century, when Canadians Frederick Banting and Charles Herbert Best isolated and purified insulin in 1921 and 1922. This was followed by the development of the long-acting insulin NPH in the 1940s.

### Etymology

The word *diabetes* (Template:IPAc-en or Template:IPAc-en) comes from Latin *diabētēs*, which in turn comes from Ancient Greek διαβήτης (*diabētēs*), which literally means "a passer through; a siphon". Ancient Greek physician Aretaeus of Cappadocia (fl. 1stTemplate:Nbspcentury CE) used that word, with the intended meaning "excessive discharge of urine", as the name for the disease. Ultimately, the word comes from Greek διαβαίνειν (*diabainein*), meaning "to pass through," which is composed of δια- (*dia*-), meaning "through" and βαίνειν (*bainein*), meaning "to go". The word "diabetes" is first recorded in English, in the form *diabete*, in a medical text written around 1425.

The word *mellitus* (Template:IPAc-en or Template:IPAc-en) comes from the classical Latin word *mellītus*, meaning "mellite" (i.e. sweetened with honey; honey-sweet). The Latin word comes from *mell*-, which comes from *mel*, meaning "honey"; sweetness; pleasant thing, and the suffix -*ītus*, whose meaning is the same as that of the English suffix "-ite". It was Thomas Willis who in 1675 added "mellitus" to the word "diabetes" as a designation for the disease, when he noticed the urine of a diabetic had a sweet taste (glycosuria). This sweet taste had been noticed in urine by the ancient Greeks, Chinese, Egyptians, Indians, and Persians.

## Society and culture

Template:Further

The 1989 "St. Vincent Declaration" was the result of international efforts to improve the care accorded to those with diabetes. Doing so is important not only in terms of quality of life and life expectancy but also economicallyTemplate:Sndexpenses due to diabetes have been shown to be a major drain on healthTemplate:Sndand productivity-related resources for healthcare systems and governments.

Several countries established more and less successful national diabetes programmes to improve treatment of the disease.

People with diabetes who have neuropathic symptoms such as numbness or tingling in feet or hands are twice as likely to be unemployed as those without the symptoms.

In 2010, diabetes-related emergency room (ER) visit rates in the United States were higher among people from the lowest income communities (526 per 10,000 population) than from the highest income communities (236 per 10,000 population). Approximately 9.4% of diabetes-related ER visits were for the uninsured.

### Naming

The term "type 1 diabetes" has replaced several former terms, including childhood-onset diabetes, juvenile diabetes, and insulin-dependent diabetes mellitus (IDDM). Likewise, the term "type 2 diabetes" has replaced several former terms, including adult-onset diabetes, obesity-related diabetes, and noninsulin-dependent diabetes mellitus (NIDDM). Beyond these two types, there is no agreed-upon standard nomenclature.Template:Citation needed

Diabetes mellitus is also occasionally known as "sugar diabetes" to differentiate it from diabetes insipidus.

## Other animals

Template:Main

In animals, diabetes is most commonly encountered in dogs and cats. Middle-aged animals are most commonly affected. Female dogs are twice as likely to be affected as males, while according to some sources, male cats are also more prone than females. In both species, all breeds may be affected, but some small dog breeds are particularly likely to develop diabetes, such as Miniature Poodles.

Feline diabetes mellitus is strikingly similar to human type 2 diabetes. The Burmese breed, along with the Russian Blue, Abyssinian, and Norwegian Forest cat breeds, showed an increased risk of DM, while several breeds showed a lower risk. There is an association between overweight and an increased risk of feline diabetes.

The symptoms may relate to fluid loss and polyuria, but the course may also be insidious. Diabetic animals are more prone to infections. The long-term complications recognized in humans are much rarer in animals. The principles of treatment (weight loss, oral antidiabetics, subcutaneous insulin) and management of emergencies (e.g. ketoacidosis) are similar to those in humans.

## Research

Inhalable insulin has been developed. The original products were withdrawn due to side effects. Afrezza, under development by the pharmaceuticals company MannKind Corporation, was approved by the United States Food and Drug Administration (FDA) for general sale in June 2014. An advantage to inhaled insulin is that it may be more convenient and easy to use.

Transdermal insulin in the form of a cream has been developed and trials are being conducted on people with typeTemplate:Nbsp2 diabetes.

### Major clinical trials

The Diabetes Control and Complications Trial (DCCT) was a clinical study conducted by the United States National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that was published in the *New England Journal of Medicine* in 1993. Test subjects all had diabetes mellitus type 1 and were randomized to a tight glycemic arm and a control arm with the standard of care at the time; people were followed for an average of seven years, and people in the treatment had dramatically lower rates of diabetic complications. It was as a landmark study at the time, and significantly changed the management of all forms of diabetes.

The United Kingdom Prospective Diabetes Study (UKPDS) was a clinical study conducted by Z that was published in *The Lancet* in 1998. Around 3,800 people with type 2 diabetes were followed for an average of ten years, and were treated with tight glucose control or the standard of care, and again the treatment arm had far better outcomes. This confirmed the importance of tight glucose control, as well as blood pressure control, for people with this condition.

## References

1. ↑ **Script error: No such module "citation/CS1".**
2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 **Script error: No such module "citation/CS1".**
3. ↑ Template:Cite journal
4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 **Script error: No such module "citation/CS1".**
5. ↑ **Script error: No such module "citation/CS1".**
6. ↑ 6.0 6.1 6.2 **Script error: No such module "citation/CS1".**
7. ↑ **Script error: No such module "citation/CS1".**
8. ↑ 8.0 8.1 Template:Cite journal
9. ↑ **Script error: No such module "citation/CS1".**
10. ↑ 10.0 10.1 **Script error: No such module "citation/CS1".**
11. ↑ 11.0 11.1 11.2 11.3 **Script error: No such module "citation/CS1".**
12. ↑ 12.0 12.1 12.2 Template:Cite journal
13. ↑ 13.0 13.1 13.2 Template:Cite journal
14. ↑ 14.0 14.1 **Script error: No such module "citation/CS1".**
15. ↑ 15.0 15.1 **Script error: No such module "citation/CS1".**
16. ↑ Template:Cite journal
17. ↑ Template:Cite journal
18. ↑ **Script error: No such module "citation/CS1".**
19. ↑ Template:Cite journal
20. ↑ Template:Cite journal
21. ↑ **Script error: No such module "citation/CS1".**
22. ↑ **Script error: No such module "citation/CS1".**
23. ↑ Template:Cite news
24. ↑ 24.0 24.1 Template:Cite journal
25. ↑ Template:Cite journal
26. ↑ Template:Cite journal
27. ↑ 27.0 27.1 27.2 27.3 **Script error: No such module "citation/CS1".**
28. ↑ **Script error: No such module "citation/CS1".**
29. ↑ Template:Cite journal
30. ↑ Template:Cite journal
31. ↑ Template:Cite journal
32. ↑ Template:Cite journal
33. ↑ Template:Cite journal
34. ↑ 34.0 34.1 **Script error: No such module "citation/CS1".**
35. ↑ Template:Cite journal
36. ↑ 36.0 36.1 Template:Cite journal
37. ↑ Template:Cite journal
38. ↑ Template:Cite journal Template:Open access
39. ↑ Template:Cite journal
40. ↑ 40.0 40.1 Template:Cite journal
41. ↑ Template:Cite journal
42. ↑ Template:Cite journal
43. ↑ Template:Cite journal
44. ↑ Template:Cite journal
45. ↑ 45.0 45.1 **Script error: No such module "citation/CS1".**
46. ↑ **Script error: No such module "citation/CS1".**
47. ↑ **Script error: No such module "citation/CS1".**
48. ↑ 48.0 48.1 **Script error: No such module "citation/CS1".**
49. ↑ Template:Cite journal
50. ↑ Unless otherwise specified, reference is: Table 20-5 in **Script error: No such module "citation/CS1".**
51. ↑ Template:Cite journal
52. ↑ Template:Cite journal
53. ↑ Template:Cite news
54. ↑ **Script error: No such module "citation/CS1".**
55. ↑ 55.0 55.1 55.2 55.3 **Script error: No such module "citation/CS1".**
56. ↑ **Script error: No such module "citation/CS1".**
57. ↑ **Script error: No such module "citation/CS1".**
58. ↑ Template:Cite journal
59. ↑ Template:Cite journal
60. ↑ **Script error: No such module "citation/CS1".**
61. ↑ **Script error: No such module "citation/CS1".**
62. ↑ Template:Cite journal
63. ↑ Template:Cite journal
64. ↑ Template:Cite journal
65. ↑ 65.0 65.1 **Script error: No such module "citation/CS1".**
66. ↑ Template:Cite journal
67. ↑ **Script error: No such module "citation/CS1".**
68. ↑ **Script error: No such module "citation/CS1".**
69. ↑ Template:Cite journal
70. ↑ Template:Cite journal
71. ↑ 71.0 71.1 Template:NICE
72. ↑ Template:Cite journal
73. ↑ Template:Cite journal
74. ↑ Template:Cite journal
75. ↑ Template:Cite journal
76. ↑ Template:Cite journal
77. ↑ Template:Cite journal
78. ↑ Template:Cite journal
79. ↑ 79.0 79.1 79.2 Template:Cite journal
80. ↑ 80.0 80.1 80.2 Cite error: Invalid `<ref>` tag; no text was provided for refs named `AFP09`
81. ↑ 81.0 81.1 Template:Cite journal
82. ↑ Template:Citation
83. ↑ Template:Cite journal
84. ↑ Template:Cite journal
85. ↑ Template:Cite journal
86. ↑ Template:Cite journal
87. ↑ Template:Cite journal
88. ↑ Template:Cite journal
89. ↑ Template:Cite journal
90. ↑ 90.0 90.1 Template:Cite journal
91. ↑ Template:Cite journal
92. ↑ Template:Cite journal
93. ↑ **Script error: No such module "citation/CS1".**
94. ↑ Template:Cite journal
95. ↑ 95.0 95.1 95.2 95.3 95.4 95.5 95.6 95.7 **Script error: No such module "citation/CS1".**
96. ↑ Template:Cite journal
97. ↑ Template:Cite journal
98. ↑ Public Health Agency of Canada, *Diabetes in Canada: Facts and figures from a public health perspective*. Ottawa, 2011.
99. ↑ Template:Cite journal
100. ↑ 100.0 100.1 Template:Cite journal
101. ↑ **Script error: No such module "citation/CS1".**
102. ↑ 102.0 102.1 102.2 102.3 102.4 102.5 102.6 102.7 102.8 **Script error: No such module "citation/CS1".**
103. ↑ 103.0 103.1 Template:Cite journal
104. ↑ 104.0 104.1 Template:Cite journal
105. ↑ 105.0 105.1 Oxford English Dictionary. *diabetes*. Retrieved 2011-06-10.
106. ↑ 106.0 106.1 **Script error: No such module "citation/CS1".**
107. ↑ Aretaeus, *De causis et signis acutorum morborum (lib. 2)*, Κεφ. β. περὶ Διαβήτεω (Chapter 2, *On Diabetes*, Greek original Template:Webarchive, on Perseus
108. ↑ 108.0 108.1 108.2 108.3 Oxford English Dictionary. *mellite*. Retrieved 2011-06-10.
109. ↑ 109.0 109.1 109.2 109.3 **Script error: No such module "citation/CS1".**
110. ↑ Oxford English Dictionary. *-ite*. Retrieved 2011-06-10.
111. ↑ **Script error: No such module "citation/CS1".**
112. ↑ Template:Cite journal
113. ↑ Template:Cite journal
114. ↑ Template:Cite journal
115. ↑ **Script error: No such module "citation/CS1".**
116. ↑ **Script error: No such module "citation/CS1".**
117. ↑ 117.0 117.1 **Script error: No such module "citation/CS1".**
118. ↑ **Script error: No such module "citation/CS1".**
119. ↑ 119.0 119.1 Template:Cite journal
120. ↑ Template:Cite journal
121. ↑ Template:Cite news
122. ↑ **Script error: No such module "citation/CS1".**
123. ↑ **Script error: No such module "citation/CS1".**
124. ↑ Template:Cite journal
125. ↑ Template:Cite journal
126. ↑ **Script error: No such module "citation/CS1".**
127. ↑ Template:Cite journal
**Script error: No such module "Check for unknown parameters".**

## External links

Template:Medical condition classification and resources
Template:Sister project links

* Template:DMOZ
* IDF Diabetes Atlas
* National Diabetes Education Program

Template:Endocrine pathology
Template:Diabetes

Template:Authority control